HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Childs, B. P. Articles by Wick, A. Search for Related Content PubMed Articles by Childs, B. P. Articles by Wick, A. Social Bookmarking                What's this?

Considering Pramlintide Therapy for Postprandial Blood Glucose Control

Address correspondence to Belinda P. Childs, ARNP, MN, BC-ADM, CDE, Mid-America Diabetes Associates, PA, 200 S. Hillside, Wichita, KS 67211.

Diabetes is a chronic disease affecting > 20 million Americans, and its incidence, especially in the form of type 2 diabetes, is increasing. Multiple therapeutics are available that address the dysregulation of the multiple hormones responsible for glucose homeostasis. Despite the various options, tight glycemic control is often elusive. Additionally, the pursuit of tight glycemic control is generally accompanied by various clinical challenges, such as hypoglycemia, weight gain, and glucose fluctuations, in particular, postprandial fluctuations.

Several therapeutic options are currently available to address postprandial glucose fluctuations, including rapid-acting insulin analogs, incretin mimetics, dipeptidyl peptidase IV inhibitors, -glucosidase inhibitors, meglitinides, and amylinomimetics. This article presents the experiences of three patients for whom pramlintide, an amylinomimetic, was identified as an appropriate therapeutic option. Practical considerations for clinicians, patient lifestyle factors, and perceptions of pramlintide therapy are also presented.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. L. Want Optimizing Treatment Success With an Amylin Analogue The Diabetes Educator, January 1, 2008; 34(1_suppl): 11S - 17S. [Abstract] [Full Text] [PDF]